MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Pharmaceutical Executive
July 1, 2006
Derek Lowe
What You Need to Know About Adaptive Trials A handful of new statistical techniques and clinical-trial designs will let you change the way you run your business. Here's your guide to the basics. mark for My Articles similar articles
Bio-IT World
June 2006
Mark D. Uehling
Real-Time Trials Currently, there is more visibility into the precise location of a FedEx package than the progress of a multimillion-dollar clinical drug trial. But adaptive design trials are changing that. mark for My Articles similar articles
Bio-IT World
October 2006
William Claypool
The Perfect Circle With the most current technologies accelerating adaptive trial designs, the future holds great promise. mark for My Articles similar articles
The Motley Fool
March 1, 2007
Brian Lawler
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2005
Lisa Grimes
Clear Road Ahead An industry standard for publicizing clinical-trial results is a ways off. But pharma's openness to more transparent procedures is moving things in the right direction. mark for My Articles similar articles
The Motley Fool
December 29, 2006
Brian Lawler
Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide. mark for My Articles similar articles
Bio-IT World
March 10, 2003
Kenneth Getz
E-Clinical Technology Overview Clinical trial researchers want to leverage the benefits of IT -- and now they can for every core process. But they also have to get past the barriers to adoption. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2006
Clinton & Koroneos
Learn & Confirm At Wyeth, a sweeping set of initiatives is transforming the R&D operation - and spotlighting a possible future for drug development. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2011
Lujing Wang
The Payoff for Payers Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval. mark for My Articles similar articles
Bio-IT World
March 10, 2003
Dawn Stover
E-Recruitment: Trial by Wire Online databases are helping patients find clinical trials -- but e-recruitment is no panacea for participant shortages. mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2013
Ken Getz
Building Clinical Trial Awareness for Patients: Why Not Try the Pharmacist? The author explains how building a stakeholder outreach agenda around the community pharmacist can lead to a better outcome in managing the complex ins and outs of a trial protocol. mark for My Articles similar articles
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2006
Sarah Houlton
Global Report: People Problems A recent clinical trials disaster is causing UK regulators to consider revising its guidelines for Phase I human studies for biologics. However, in many cases, potential solutions present additional problems. mark for My Articles similar articles
The Motley Fool
September 13, 2007
Brian Orelli
Alfacell's Awkward Wait Waiting for subjects to die is a somber part of the oncology clinical trial process. Alfacell is doing just that in its final phase three trial with its lead cancer drug candidate. Investors take note. mark for My Articles similar articles
The Motley Fool
December 27, 2006
Brian Lawler
Telik Falls Short Shares of another biopharma fall after disappointing clinical trial results. mark for My Articles similar articles
Bio-IT World
August 2005
Ellen H. Julian
Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources. mark for My Articles similar articles
Pharmaceutical Executive
November 1, 2006
Unraveling the eSource Industry-wide standards for electronic patient data have long felt like buried treasure. Companies today are getting closer - by way of a tangled map. mark for My Articles similar articles
Pharmaceutical Executive
July 1, 2012
William Looney
Today's Mission Critical: Making Sense of Spending on Clinical Trials Mastery of the clinical trial process has become essential to positioning new therapies for leadership in an increasingly crowded and lengthy race to registration. mark for My Articles similar articles
The Motley Fool
May 31, 2011
Brian Orelli
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. mark for My Articles similar articles
Pharmaceutical Executive
May 1, 2007
Weiner & Hovde
Critical Mass for Critical Path? Everyone agrees that it's the road to pharma's future, but no one's rushing to take it. Yet with growing FDA advocacy and new advances in biomarkers and drug-disease modeling, the rewards of collaboration now look greater than the risks. mark for My Articles similar articles
The Motley Fool
June 29, 2007
Brian Orelli
The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials. mark for My Articles similar articles
Pharmaceutical Executive
May 1, 2006
Madison, Chan & Seeger
Making the Link The FDA recognizes that a new drug standard must evolve -- one of routine, proactive safety surveillance. But post-marketing safety studies are too slow. Here's how pharmaceuticals are using claims databases to solve the problem. mark for My Articles similar articles
AskMen.com
Richard Stevens
Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process. mark for My Articles similar articles
Bio-IT World
May 9, 2003
Mark D. Uehling
Data Rapture? Electronic capture of data: Some say it unclogs the medieval clinical trials process. Others remain skeptical of software and put their trust in paper. mark for My Articles similar articles
The Motley Fool
December 29, 2011
Brian Orelli
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. mark for My Articles similar articles
The Motley Fool
July 10, 2006
Brian Lawler
Northfield Frowns on Focus From "20/20" The maker of artificial blood finds yet another critic. But the impending end of the PolyHeme trial probably won't represent the end of criticism of the artificial blood. Only if good clinical trial results are announced later this year will Northfield's critics be silenced. mark for My Articles similar articles
Bio-IT World
April 16, 2004
Joel Hoffman
Taking the Trial Out of Clinical Outsourcing Make sure the vendor's standard operating procedures will mesh with your own, and then tirelessly work toward systems integration. mark for My Articles similar articles
Bio-IT World
January 21, 2005
John Otrompke
Recruiting in the Workplace With hundreds of new therapeutic agents in the pipeline, it is no wonder that clinical trials sponsors are looking to organize trials around the workplace. mark for My Articles similar articles
Reason
Aug/Sep 2007
Kerry Howley
Dying for Lifesaving Drugs Will desperate patients destroy the pharmaceutical system that produces tomorrow's treatments? mark for My Articles similar articles
Chemistry World
October 15, 2013
Dinsa Sachan
Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed. mark for My Articles similar articles
Bio-IT World
March 8, 2005
Mark D. Uehling
Is That a Target on Her Back? Q&A with Deborah Zarin, head of ClinicalTrials.gov, the matchmaking Web site for patients seeking to participate in federally sponsored clinical trials. mark for My Articles similar articles
Bio-IT World
July 2005
Mark D. Uehling
'E-source' Is Coming, Experts Say The odd marriages of the ancient and modern in clinical technologies were in evidence at the E-Clinical Trials & Research conference program. There was evidence of the adoption of advanced and robust commercial software -- even toward clinical trials that do not use paper, though most do. mark for My Articles similar articles
Bio-IT World
August 13, 2002
Mark D. Uehling
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? mark for My Articles similar articles
Chemistry World
September 2007
Derek Lowe
Column: In the Pipeline Will Phase Zero trials actually help drug development? mark for My Articles similar articles
The Motley Fool
August 16, 2007
Brian Orelli
Novacea's (Statistically) Significant Change The pharmaceutical increases the number of subjects in its latest clinical trial. mark for My Articles similar articles
Bio-IT World
February 2007
Kevin Davies
Ten Years After: Learn and Confirm Wyeth faces the same problems bedeviling the industry: the soaring cost of development is matched only by the rising attrition rate as once promising drug candidates fall by the wayside. But a new strategy leads to a more science-driven model. mark for My Articles similar articles
Wired
March 2006
Jennifer Kahn
A Nation of Guinea Pigs There's a new outsourcing boom in South Asia - and a billion people are jockeying for the jobs. How India became the global hot spot for drug trials. mark for My Articles similar articles
Chemistry World
August 7, 2013
Emma Stoye
AllTrials releases plan for clinical trial reporting The organizations behind AllTrials, a public campaign calling for detailed information on clinical trials to be publically available, have put together a detailed plan on how to achieve clinical trial reporting on a global scale. mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2008
Melanie North
Publish or Perish FDAAA means that companies need to register clinical trials; and not only for publication planning. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2007
Dinh Nguyen
Clinical Trials Under Scrutiny Over the last few years, there has been a growing number of instances of misconduct in clinical research. mark for My Articles similar articles
Information Today
July 2, 2013
Thomson Reuters Offers Clinical Trial Intelligence Solutions These solutions improve clinical trials, speed up product development and release, and help professionals strengthen portfolios and R&D strategy. mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2013
Jill Wechsler
Biopharma Innovation in Trouble? Regulators, sponsors seek more productive research strategies. mark for My Articles similar articles
Bio-IT World
December 15, 2003
Mark D. Uehling
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials. mark for My Articles similar articles
Information Today
December 10, 2012
Thomson Reuters Announces Cortellis for Clinical Trials Intelligence Scheduled for release in early 2013, this capability will provide drug development and clinical professionals with the critical information. mark for My Articles similar articles
The Motley Fool
May 9, 2007
Mike Havrilla
Scintillating Synta Patient investors should peek at this pharma's promising pipeline. mark for My Articles similar articles
The Motley Fool
August 27, 2007
Brian Orelli
Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up. mark for My Articles similar articles
Managed Care
July 2005
Martin Sipkoff
Support Grows for Establishing National Clinical Trial Registry Stakeholders are pushing for a national clinical trial registry, and efforts by UnitedHealth Group are in the forefront. Medical journals are setting hard and fast rules. mark for My Articles similar articles
Investment Advisor
December 2005
Greg B. Scott
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2006
Jill Wechsler
Washington Report: Promises to Keep Congress wants pharma to meet study commitments and disclose research results, but no one is giving FDA more resources to enforce its rules. mark for My Articles similar articles